KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval
・Karyopharm’s Phase 3 SENTRY trial met its primary endpoint, with 50% of patients on selinexor combined with ruxolitinib achieving significant spleen reduction versus 28% on ruxolitinib alone. ・Across secondary and exploratory endpoints, no meaningful...
Stocktwits